共 38 条
[21]
Hoelzer D., Gokbuget N., Bruggemann M., Et al., Clinical impact of minimal residual disease (MRD) in trial design for adult ALL, Blood, 98, (2001)
[22]
Hoelzer D., Ludwig W.D., Thiel E., Et al., Improved outcome in adult B-cell acute lymphoblastic leukemia, Blood, 87, pp. 495-508, (1996)
[23]
Hoelzer D., Thiel E., Loffler H., Et al., Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults, Blood, 71, pp. 123-131, (1988)
[24]
Hoelzer D., Thiel E., Ludwig W.D., Et al., Follow-up of the first two successive German multicentre trials for adult ALL (01/81 and 02/84), Leukemia Suppl, 2, pp. 130-134, (1993)
[25]
Kantarjian H.M., O'Brien S., Smith T.L., Et al., Results of treatment with hyper-CVAD, a dose-intensive regimen, in ad ult acute lymphocytic leukemia, J Clin Oncol, 18, pp. 547-561, (2000)
[26]
Krackhardt A., Schwartz S., Thiel E., Targeting folates by carboxypeptidase G2: Potential applications in anticancer therapy, Onkologie, 23, pp. 538-543, (2000)
[27]
Larson R.A., Dodge R.K., Burns C.P., Et al., A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B study 8811, Blood, 85, pp. 2025-2037, (1995)
[28]
Larson R.A., Dodge R.K., Linker C.A., Et al., A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111, Blood, 92, pp. 1556-1564, (1998)
[29]
Ludwig W.D., Rieder H., Bartram C.R., Et al., Immunophenotypic and genotypic features, clinical characteristics, and treatment outcome of adult pro-B acute lymphoblastic leukemia: Results of the German multicenter trials GMALL 03/87 and 04/89, Blood, 92, pp. 1898-1909, (1998)
[30]
Ludwig W.D., Raghavachar A., Thiel E., Immunophenotypic classification of acute lymphoblastic leukemia, Bailliere's Clin Haematol, 7, (1994)